Dr. Lynnette Averill is experienced in translational clinical neuroscience, and is an expert in the evaluation of neurocognitive symptoms and the clinical assessment and treatment of PTSD, suicidality, and other trauma- and stress-related psychopathology. Her work focuses on pharmacoimaging trials evaluating rapid-acting glutamatergic-based drugs (e.g., ketamine) on reductions in suicidal ideation and cognitive function and the neural underpinnings (e.g., synaptic connectivity) of these behavioral changes.